Ausgabe 3/2016
Inhalt (23 Artikel)
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Roger M. Phillips
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
Dan Lu, Tong Lu, Mark Stroh, Richard A. Graham, Priya Agarwal, Luna Musib, Chi-Chung Li, Bert L. Lum, Amita Joshi
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma
Carmen Belli, Lorenzo Piemonti, Maurizio D’Incalci, Massimo Zucchetti, Luca Porcu, Stefano Cappio, Claudio Doglioni, Paola Allavena, Domenica Ceraulo, Paola Maggiora, Erica Dugnani, Maria Giulia Cangi, Greta Garassini, Michele Reni
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer
Mark Stroh, Michelle Green, Edward Cha, Nancy Zhang, Russ Wada, Jin Jin
Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors
Viktor Arnhold, Joachim Boos, Claudia Lanvers-Kaminsky
Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma
Chao Shang, Yan Guo, Hui Zhang, Yi-xue Xue
Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry
James J. Lee, Jabed Seraj, Kenichiro Yoshida, Hirokazu Mizuguchi, Sandra Strychor, Jillian Fiejdasz, Tyeler Faulkner, Robert A. Parise, Patrick Fawcett, Laura Pollice, Scott Mason, Jeremy Hague, Marie Croft, James Nugteren, Charles Tedder, Weijing Sun, Edward Chu, Jan Hendrik Beumer
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors
Justine Yang Bruce, Patricia M. LoRusso, Priscila H. Goncalves, Elisabeth I. Heath, Elizabeth Sadowski, David R. Shalinsky, Yanwei Zhang, Anne M. Traynor, Aurora Breazna, Alejandro D. Ricart, Michael Tortorici, Glenn Liu
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer
Su Jin Heo, Inkyung Jung, Choong-kun Lee, Jee Hung Kim, Sun Min Lim, Yong Wha Moon, Hyo Sup Shim, Jaeheon Jeong, Joo-Hang Kim, Hye Ryun Kim, Byoung Chul Cho
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors
Jason J. Luke, Patricia LoRusso, Geoffrey I. Shapiro, Andrew Krivoshik, Robin Schuster, Takao Yamazaki, Yukinori Arai, Allam Fakhoury, Carl Dmuchowski, Jeffrey R. Infante
Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy
Yusuke Takagi, Yukio Hosomi, Makoto Nagamata, Kageaki Watanabe, Satoshi Takahashi, Yoshiro Nakahara, Makiko Yomota, Kuniko Sunami, Yusuke Okuma, Tsuneo Shimokawa, Tatsuru Okamura
Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer
Hugh Giovinazzo, Parag Kumar, Arif Sheikh, Kristina M. Brooks, Marija Ivanovic, Mark Walsh, Whitney P. Caron, Richard J. Kowalsky, Gina Song, Ann Whitlow, Daniel L. Clarke-Pearson, Wendy R. Brewster, Linda Van Le, Beth A. Zamboni, Victoria Bae-Jump, Paola A. Gehrig, William C. Zamboni
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer
Rabih Said, Yang Ye, David S. Hong, Aung Naing, Gerald Falchook, Siqing Fu, Jennifer J. Wheler, Sarina Piha-Paul, Apostolia-Maria Tsimberidou
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance
Quan Zhang, Tianyu Sun, Poming Kang, Kai Qian, Bo Deng, Jinghai Zhou, Ruwen Wang, Bin Jiang, Kun Li, Fang Liu, Shiyang Wu, Qunyou Tan
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Hideki Ueno, Masafumi Ikeda, Makoto Ueno, Nobumasa Mizuno, Tatsuya Ioka, Yasushi Omuro, Takako Eguchi Nakajima, Junji Furuse
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer
Hyun-Jeong Shim, Ka-Rham Kim, Jun-Eul Hwang, Woo-Kyun Bae, Seong-Yeop Ryu, Young-Kyu Park, Taek-Keun Nam, Ik-Joo Chung, Sang-Hee Cho
Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription
Pingjiang Ye, Haibo Xing, Fang Lou, Kaifeng Wang, Qin Pan, Xiaoyun Zhou, Liu Gong, Da Li
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation
Yasushi Yoshimura, Mitsue Kurasawa, Keigo Yorozu, Oscar Puig, Walter Bordogna, Naoki Harada
UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy
Ling Zhang, Xili Cao, Liqian Zhang, Xuelin Zhang, Haihui Sheng, Kun Tao
Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab
Shruti Agrawal, Ian Waxman, Alexandre Lambert, Amit Roy, Raymond Darbenzio
Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma
Zibin Liang, Siyang Wang, Zhong Lin, Shaoyan Feng, Zhibin Cheng, Yaqi Yang, Ying Kuang, Chibhabha Fidelis, Shahid Ullah, Feng Li
The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy
Alessia Dalla Pria, Maggie Bendle, Ramya Ramaswami, Marta Boffito, Mark Bower
Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice
Viviane Costa Junqueira Rocha, Luciana Souza de Aragão França, Cintia Figueiredo de Araújo, Ayling Martins Ng, Candace Machado de Andrade, André Cronemberger Andrade, Emanuelle de Souza Santos, Mariana da Cruz Borges-Silva, Simone Garcia Macambira, Alberto Augusto Noronha-Dutra, Lain Carlos Pontes-de-Carvalho